臨床試験用資材市場規模、シェア、動向、2031年までの世界予測 - by drug type

臨床試験用資材市場規模、シェア、動向、2031年までの世界予測

Clinical Trial Supplies Market - Global Forecast to 2031

臨床試験用資材市場 - サービス(製造、包装[一次・二次]、物流)、開発段階、種類(低分子医薬品、バイオ医薬品、ワクチン)、治療領域(腫瘍学、神経学、眼科学、皮膚科学)、地域 ― 2031年までの世界市場予測

Clinical Trial Supplies Market by Service [Manufacturing, Packaging (Primary, Secondary), Logistics], Phases, Type (Small Molecules, Biologics, Vaccine), Therapeutic Areas (Oncology, Neurology, Ophthalmology, Dermatology), Region - Global Forecast to 2031


出版 MarketsandMarkets
出版年月 2026年10月
ページ数 449
図表数 634
価格 記載以外のライセンスについてはお問合せください
 シングルユーザ USD 4,950
種別 英文調査報告書
商品番号 SMR-29273


SEMABIZ - otoiawase8

臨床試験用資材市場は、2026年の56億米ドルから2031年には89億5,000万米ドルに達し、同期間の年平均成長率(CAGR)は9.8%になるとMarketsandMarketsでは予測されています。臨床試験数の増加、製薬・バイオテクノロジー企業による研究開発(R&D)費の拡大、そしてスポンサーによるグローバル、多施設共同、分散型、および適応型試験の実施拡大に伴い、市場は成長すると見込まれています。こうした変化は、規制に準拠した調達、包装・ラベリング、保管、温度管理された配送、およびリアルタイムでの供給状況の可視化に対する需要を高めています。一方で、対照薬の調達、コールドチェーン管理、国ごとのラベリング対応、保管、輸送にかかる高額なコストが、試験予算を増大させる要因となる可能性があります。また、医薬品不足、地政学的混乱、複雑な輸入要件、不正確な需要予測なども、納期の遅延や製品の廃棄増大を招く恐れがあります。

調査対象範囲

本調査レポートでは、臨床試験用資材市場をサービス、試験フェーズ、種類、治療領域、エンドユーザー、および地域別に分類しています。対象となるサービスには、物流・配送、包装、ラベリング・盲検化、保管・保持、製造、対照薬の調達、その他サービスが含まれます。また、フェーズI~IVおよび生物学的利用能/生物学的同等性(BA/BE)試験、低分子医薬品・バイオ医薬品・医療機器、主要な治療領域についても評価を行っています。エンドユーザーには、製薬・バイオテクノロジー企業、CRO(医薬品開発受託機関)およびCDMO(医薬品受託開発製造機関)、ならびに医療機器企業や学術・研究機関などの組織が含まれます。市場の促進要因、阻害要因、機会、および課題に関する詳細な分析も範囲に含まれています。さらに、主要なプロバイダーについて、事業概要、サービスポートフォリオ、提携、買収、事業拡大、契約、その他臨床試験用資材市場に関連する最近の動向を通じて評価を行います。競争分析では、市場エコシステム全体にわたる既存の有力企業および新興企業を対象としています。

本レポートを購入する主なメリット

本レポートは、臨床試験用資材市場全体およびそのサブセグメントの収益に関する極めて精度の高い推定値を提供することで、市場のリーダー企業や新規参入企業を支援します。ステークホルダーは、主要プロバイダーの競争上の地位やサービス能力を比較し、自社の事業拡大戦略に合致する市場を特定することができます。また、サービス、試験フェーズ、治療の種類、治療領域、エンドユーザー、地域ごとの市場需要を把握することも可能です。さらに、臨床試験の実施状況、サプライチェーン・コスト、分散型臨床試験(DCT)モデル、デジタル供給技術、医薬品不足、規制の複雑さなど、成長を左右する要因についても網羅しています。

本レポートでは、以下の点に関する洞察を提供します:

臨床試験用資材市場の成長に影響を与える主要因の分析:促進要因(臨床試験および医薬品開発の増加、グローバル試験や多施設共同試験の拡大、個別化医療やバイオ医薬品への需要増)、阻害要因(臨床試験用資材に関連する高コスト)、機会(分散型・バーチャル臨床試験、デジタル・サプライチェーン技術の統合)、課題(サプライチェーンの混乱、医薬品不足、国ごとに異なる複雑な要件)

  • サービス開発・イノベーション:対照薬の調達、患者への直接配送(DTP)、デジタル追跡、コールドチェーン物流など、新規および拡充された臨床試験用資材供給サービスに関する詳細な知見
  • 市場開拓:北米、欧州、アジア太平洋、中南米、中東・アフリカにおける臨床試験用資材供給市場の分析および有望な市場に関する包括的な情報
  • 市場の多角化:臨床試験用資材供給市場における新規サービス、未開拓地域、最近の動向、提携、買収、供給能力の拡大、投資に関する詳細情報
  • 競合状況の評価:Thermo Fisher Scientific Inc.(米国)、Almac Group(英国)、Novo Holdings A/S (Catalent, Inc.)(デンマーク/米国)、Marken (UPS)(米国)、PCI Pharma Services(米国)などの主要企業を対象とした、市場シェア、成長戦略、サービスポートフォリオに関する詳細な評価

Report Description

The clinical trial supplies market is projected to reach USD 8.95 billion by 2031, up from USD 5.60 billion in 2026, at a 9.8% CAGR from 2026 to 2031. The market is expected to grow as the number of clinical trials rises, pharmaceutical and biotechnology R&D spending expands, and sponsors conduct more global, multicenter, decentralized, and adaptive studies. These changes increase demand for compliant sourcing, packaging and labeling, storage, temperature-controlled distribution, and real-time supply visibility. However, high costs for comparator procurement, cold-chain handling, country-specific labeling, storage, and transportation can increase trial budgets. Drug shortages, geopolitical disruption, complex import requirements, and inaccurate demand forecasts may also delay deliveries and increase product wastage.

臨床試験用資材市場規模、シェア、動向、2031年までの世界予測

Clinical Trial Supplies Market – Global Forecast to 2031

“Logistics & distribution services accounted for the largest share, by service, in 2024 and continued to lead in 2025.”

Based on service, the clinical trial supplies market is segmented into sourcing & procurement; packaging & labeling; logistics & distribution; storage & retention; and other services, including biological sample management, destruction & waste management, and kit assembly. Logistics & distribution services held the largest share in 2025. This large share highlights the growing need to move investigational products, comparators, medical devices, and ancillary supplies across dispersed sites while maintaining chain of custody and product stability. Growth in biologics, vaccines, and cell & gene therapies is increasing demand for cold-chain, cryogenic, and ultra-low-temperature capabilities. Decentralized and direct-to-patient models further expand delivery destinations and require tighter coordination, monitoring, and returns management.

“The small molecules segment accounted for the largest share of the clinical trial supplies market, by type, in 2025.”

Based on type, the global clinical trial supplies market is segmented into small molecules, biologics, and medical devices. Small molecules accounted for the largest share of market revenue in 2025, supported by established manufacturing processes, cost-efficient production, ease of oral administration, and broad use across oncology, cardiovascular, neurological, and infectious diseases. Biologics include monoclonal antibodies, vaccines, cell & gene therapies, recombinant proteins, plasma-derived products, biosimilars, and peptides. Many of these products require refrigerated, frozen, or cryogenic handling and continuous temperature monitoring. Medical-device trials add requirements for component control, study-specific labeling, device accountability, and controlled distribution. The resulting range of dosage forms, stability profiles, and handling requirements sustains demand for specialized clinical supply partners with global quality and logistics capabilities.

臨床試験用資材市場規模、シェア、動向、2031年までの世界予測 - 地域

Clinical Trial Supplies Market – Global Forecast to 2031 – by region

“Asia Pacific is expected to grow at the highest CAGR in the clinical trial supplies market during the forecast period.”

The clinical trial supplies market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is estimated to record the highest CAGR during the forecast period, supported by expanding pharmaceutical and biopharmaceutical industries, competitive trial costs, favorable government policies, and a growing CRO base. The region is attracting more multinational trials, which increases demand for local depots, import and export support, country-specific labeling, comparator sourcing, and temperature-controlled delivery. North America accounted for the largest share of market revenue in 2025, supported by the adoption of decentralized trials and advanced cold-chain logistics. Europe also remains an important market because of its established clinical research infrastructure and substantial multinational study activity.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side – 70% and Demand Side – 30%
  • By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
  • By Designation: CXOs and Directors – 30%, Managers – 45%, and Others – 25%
  • By Region: North America – 35%, Europe – 25%, Asia Pacific – 20%, Latin America – 10%, the Middle East – 5%, and Africa – 5%
臨床試験用資材市場規模、シェア、動向、2031年までの世界予測 - 対象企業

Clinical Trial Supplies Market – Global Forecast to 2031 – by ecosystem

List of Companies Profiled in the Report

  • Thermo Fisher Scientific Inc.
  • Almac Group
  • Novo Holdings A/S (Catalent, Inc.)
  • Marken (UPS)
  • PCI Pharma Services
  • Piramal Group
  • Sharp Services LLC
  • Cencora, Inc.
  • Myonex
  • Clinigen Limited
  • Inceptua Group
  • Eurofins Scientific
  • Parexel International Corporation
  • ICON plc
  • IQVIA
  • BioCair
  • Lonza

Research Coverage

This research report categorizes the clinical trial supplies market by service, phase, type, therapeutic area, end user, and region. Services covered include logistics & distribution, packaging, labeling & blinding, storage & retention, manufacturing, comparator sourcing, and other services. The report assesses Phase I, Phase II, Phase III, Phase IV, and bioavailability/bioequivalence studies; small molecules, biologics, and medical devices; and major therapeutic areas. End users include pharmaceutical & biotechnology companies, CROs & CDMOs, and other organizations such as medical-device companies and academic & research institutes. The scope includes detailed analysis of market drivers, restraints, opportunities, and challenges. It also evaluates leading providers through their business overview, service portfolio, partnerships, acquisitions, expansions, agreements, and other recent developments associated with the clinical trial supplies market. Competitive analysis covers established players and emerging companies across the market ecosystem.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall clinical trial supplies market and its subsegments. It will help stakeholders compare the competitive position and service capabilities of major providers and identify markets aligned with their expansion strategies. The report will also enable stakeholders to understand market demand across services, trial phases, therapy types, therapeutic areas, end users, and regions. It covers factors shaping growth, including clinical trial activity, supply-chain costs, decentralized trial models, digital supply technologies, drug shortages, and regulatory complexity.

The report provides insights into the following pointers:

Analysis of key drivers (growth in clinical trials and drug development, expansion of global and multicenter trials, and rising demand for personalized medicines and biologics), restraints (high costs associated with clinical trial supplies), opportunities (decentralized and virtual trials and the integration of digital supply-chain technologies), and challenges (supply-chain disruptions, drug shortages, and complex country-specific requirements) influencing the growth of the clinical trial supplies market

  • Service Development/Innovation: Detailed insights into new and expanded clinical trial supply services, including comparator sourcing, direct-to-patient delivery, digital tracking, and cold-chain logistics
  • Market Development: Comprehensive information about attractive markets and analysis of the clinical trial supplies market across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
  • Market Diversification: Detailed information about new services, untapped geographies, recent developments, partnerships, acquisitions, capacity expansions, and investments in the clinical trial supplies market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service portfolios of leading players such as Thermo Fisher Scientific Inc. (US), Almac Group (UK), Novo Holdings A/S (Catalent, Inc.) (Denmark/US), Marken (UPS) (US), and PCI Pharma Services (US), among others

Table of Contents

1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 42
1.3 MARKET SCOPE 43
1.3.1 MARKETS & REGIONS COVERED 43
1.3.2 INCLUSIONS & EXCLUSIONS 44
1.3.3 YEARS CONSIDERED 44
1.3.4 CURRENCY CONSIDERED 45
1.4 STAKEHOLDERS 45
1.5 SUMMARY OF CHANGES 45
2 EXECUTIVE SUMMARY 47
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 47
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 49
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 50
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 51
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 52
3 PREMIUM INSIGHTS 53
3.1 CLINICAL TRIAL SUPPLIES MARKET OVERVIEW 53
3.2 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE AND COUNTRY (2025) 54
3.3 CLINICAL TRIAL SUPPLIES MARKET SHARE, BY TYPE, 2026 VS. 2031 54
3.4 CLINICAL TRIAL SUPPLIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
4 MARKET OVERVIEW 56
4.1 INTRODUCTION 56
4.2 MARKET DYNAMICS 56
4.2.1 DRIVERS 57
4.2.1.1 Growth in clinical trials & drug development 57
4.2.1.2 Expansion of global and multicenter trials accelerating demand for clinical trial supplies 58
4.2.1.3 Rising demand for personalized medicine and biologics 58
4.2.2 RESTRAINTS 59
4.2.2.1 High costs associated with clinical trial supplies 59
4.2.3 OPPORTUNITIES 59
4.2.3.1 Rise in decentralized and virtual trials 59
4.2.3.2 Integration of digital technologies in supply chain management 60
4.2.4 CHALLENGES 60
4.2.4.1 Supply chain disruptions and drug shortages 60
4.3 UNMET NEEDS AND WHITE SPACES 61
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 62
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 THREAT OF NEW ENTRANTS 64
5.1.2 BARGAINING POWER OF SUPPLIERS 64
5.1.3 BARGAINING POWER OF BUYERS 65
5.1.4 THREAT OF SUBSTITUTES 65
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.2 MACROECONOMIC OUTLOOK 65
5.2.1 INTRODUCTION 65
5.2.2 GDP TRENDS AND FORECAST 66
5.2.3 TRENDS IN GLOBAL CLINICAL TRIAL SUPPLIES MARKET 66
5.3 VALUE CHAIN ANALYSIS 67
5.4 ECOSYSTEM ANALYSIS 69
5.4.1 CLINICAL TRIAL SUPPLIES MARKET: RAW MATERIAL PROVIDERS 69
5.4.2 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS 70
5.4.3 CLINICAL TRIAL SUPPLIES MARKET: END USERS 70
5.4.4 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES 71
5.5 PRICING ANALYSIS 71
5.5.1 AVERAGE SELLING PRICE, BY KEY PLAYER (QUALITATIVE) 71
5.5.2 INDICATIVE PRICE, BY SERVICE (QUALITATIVE) 72
5.6 INVESTMENT AND FUNDING SCENARIO 73
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
5.8 KEY CONFERENCES AND EVENTS, 2026–2027 75
5.9 IMPACT OF 2025 US TARIFFS—CLINICAL TRIAL SUPPLIES MARKET 76
5.9.1 INTRODUCTION 76
5.9.2 KEY TARIFF RATES 76
5.9.3 PRICE IMPACT ANALYSIS 76
5.9.4 IMPACT ON COUNTRIES/REGIONS 77
5.9.4.1 North America 77
5.9.4.1.1 US 77
5.9.4.2 Europe 77
5.9.4.3 Asia Pacific 78
5.9.5 IMPACT ON END-USE INDUSTRIES 78
5.9.5.1 Pharmaceutical & biotech companies 78
5.9.5.2 Medical devices companies 79
5.9.5.3 Academic institutes 79
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS AND FUTURE APPLICATIONS 80
6.1 TECHNOLOGY ANALYSIS 80
6.1.1 KEY TECHNOLOGIES 80
6.1.1.1 Serialization & track-and-trace technologies 80
6.1.1.2 Interactive response technology (IRT/IVR/IWR) 80
6.1.1.3 Cold chain & temperature monitoring solutions 80
6.1.2 COMPLEMENTARY TECHNOLOGIES 81
6.1.2.1 Artificial intelligence (AI) & machine learning (ML) 81
6.1.2.2 Blockchain for supply chain transparency 81
6.1.3 ADJACENT TECHNOLOGIES 81
6.1.3.1 Cryopreservation & advanced storage technologies 81
6.1.3.2 Advanced robotics in warehousing & distribution 81
6.2 TECHNOLOGY/PRODUCT ROADMAP 81
6.3 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SUPPLIES MARKET 82
6.3.1 TOP USE CASES AND MARKET POTENTIAL 82
6.3.2 CASE STUDIES OF AI IMPLEMENTATION IN CLINICAL TRIAL SUPPLIES MARKET 83
6.3.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 83
6.3.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CLINICAL TRIAL SUPPLIES MARKET 84
7 REGULATORY LANDSCAPE 85
7.1 REGIONAL REGULATIONS AND COMPLIANCE 85
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
7.1.2 REGULATORY FRAMEWORK 88
7.1.2.1 North America 88
7.1.2.1.1 US 88
7.1.2.1.2 Canada 89
7.1.2.2 Europe 89
7.1.2.2.1 Germany 89
7.1.2.2.2 France 89
7.1.2.2.3 Italy 89
7.1.2.3 Asia Pacific 89
7.1.2.3.1 Japan 89
7.1.2.3.2 China 89
7.1.2.3.3 India 89
7.1.2.4 Latin America 90
7.1.2.4.1 Brazil 90

7.1.2.5 Middle East & Africa 90
7.1.2.5.1 GCC Countries 90
7.1.2.5.2 South Africa 90
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 91
8.1 DECISION-MAKING PROCESS 91
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 92
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
8.2.2 KEY BUYING CRITERIA, BY END USER 93
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 94
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 95
8.5 MARKET PROFITABILITY 95
9 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE 97
9.1 INTRODUCTION 98
9.2 LOGISTICS & DISTRIBUTION SERVICES 98
9.2.1 RISING DEMAND DUE TO INCREASING EMPHASIS ON CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH 98
9.3 STORAGE & RETENTION SERVICES 102
9.3.1 RISING DEMAND FOR ULTRA-LOW-TEMPERATURE STORAGE TO DRIVE GROWTH 102
9.4 PACKAGING, LABELING, AND BLINDING SERVICES 105
9.4.1 PRIMARY PACKAGING SERVICES 109
9.4.1.1 Increasing demand for innovative drug formulations to support market growth 109
9.4.2 SECONDARY PACKAGING SERVICES 112
9.4.2.1 Increasing complexity of global clinical trials to propel market 112
9.4.3 LABELING & BLINDING SERVICES 115
9.4.3.1 Rising number of randomized and double-blind studies to propel market 115
9.5 MANUFACTURING SERVICES 118
9.5.1 RISING COMPLEXITY OF TRIALS, DEMAND FOR BIOLOGICS, AND RELIANCE ON CDMOS TO DRIVE MARKET 118
9.6 COMPARATOR SOURCING SERVICES 121
9.6.1 RISING DEMAND FOR COMPARATOR SOURCING TO DRIVE MARKET 121
9.7 OTHER SERVICES 125

10 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE 129
10.1 INTRODUCTION 130
10.2 PHASE III 130
10.2.1 DEVELOPMENT OF BIOLOGICS AND ADVANCED THERAPIES TO SUPPORT MARKET GROWTH 130
10.3 PHASE II 134
10.3.1 NEED FOR GREATER EFFICIENCY AND COMPLIANCE IN TRIAL LOGISTICS TO SUPPORT MARKET GROWTH 134
10.4 PHASE I 137
10.4.1 RISING COMPLEXITY OF INVESTIGATIONAL DRUGS TO DRIVE MARKET GROWTH 137
10.5 PHASE IV 141
10.5.1 INCREASING FOCUS ON PATIENT-CENTRIC APPROACHES TO DRIVE MARKET GROWTH 141
10.6 PHASE BA/BE 144
10.6.1 ACCELERATING GENERIC DRUG APPROVALS THROUGH OPTIMIZED BA/BE STUDIES TO SUPPORT MARKET GROWTH 144
11 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE 148
11.1 INTRODUCTION 149
11.2 SMALL MOLECULES 149
11.2.1 HIGH VOLUME OF SMALL-MOLECULE CLINICAL TRIALS 149
11.3 BIOLOGICS 153
11.3.1 MONOCLONAL ANTIBODIES 157
11.3.1.1 Rising demand for monoclonal antibodies to drive growth 157
11.3.2 VACCINES 160
11.3.2.1 Increased focus on development of novel vaccines to drive growth 160
11.3.3 OTHER BIOLOGICS 164
11.4 MEDICAL DEVICES 167
11.4.1 RISING DEMAND FOR SPECIALIZED LOGISTICS IN MEDICAL DEVICE CLINICAL TRIALS TO DRIVE MARKET GROWTH 167
12 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA 171
12.1 INTRODUCTION 172
12.2 ONCOLOGY 173
12.2.1 RISING DISEASE BURDEN TO SUPPORT MARKET GROWTH 173
12.3 NEUROLOGY 177
12.3.1 INCREASING R&D INVESTMENT TO SUPPORT MARKET GROWTH 177
12.4 RESPIRATORY DISORDERS 181
12.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH 181

12.5 METABOLIC DISORDERS/ENDOCRINOLOGY 184
12.5.1 INCREASING GLOBAL DIABETES POPULATION TO SUPPORT MARKET GROWTH 184
12.6 CARDIOVASCULAR SYSTEM DISORDERS 188
12.6.1 RISING DEMAND IN CLINICAL DIAGNOSTICS TO PROPEL MARKET GROWTH 188
12.7 DERMATOLOGY 191
12.7.1 GROWING FOCUS ON DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 191
12.8 GASTROINTESTINAL SYSTEM DISORDERS 195
12.8.1 INCREASING INCIDENCE OF LIFESTYLE AND DIETARY RISK FACTORS TO DRIVE DEMAND 195
12.9 IMMUNOLOGIC DISORDERS 198
12.9.1 GROWING CLINICAL RESEARCH TO SUPPORT MARKET GROWTH 198
12.10 INFECTIOUS DISEASES 202
12.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH 202
12.11 PSYCHIATRY 206
12.11.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH 206
12.12 OPHTHALMOLOGY 209
12.12.1 RISING NUMBER OF OPHTHALMIC PIPELINE DRUGS TO AID MARKET GROWTH 209
12.13 HEMATOLOGY 213
12.13.1 INTEGRATION OF ADVANCED SUPPLY CHAIN TECHNOLOGIES TO FUEL MARKET GROWTH 213
12.14 GENITOURINARY & WOMEN’S HEALTH 216
12.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET GROWTH 216
12.15 OTHER THERAPEUTIC AREAS 220
13 CLINICAL TRIAL SUPPLIES MARKET, BY END USER 224
13.1 INTRODUCTION 225
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 225
13.2.1 EXPANDING R&D PIPELINES AND INCREASING TRIAL COMPLEXITY TO DRIVE DEMAND FOR CLINICAL TRIAL SUPPLIES 225
13.3 CROS 229
13.3.1 INCREASING INTEGRATION OF CLINICAL OPERATIONS AND SUPPLY CHAIN MANAGEMENT TO DRIVE MARKET GROWTH 229
13.4 MEDICAL DEVICE COMPANIES 232
13.4.1 RISING CLINICAL EVIDENCE REQUIREMENTS AND DEVICE INNOVATION TO DRIVE DEMAND FOR CLINICAL TRIAL SUPPLIES 232

14 CLINICAL TRIAL SUPPLIES MARKET, BY REGION 236
14.1 INTRODUCTION 237
14.2 NORTH AMERICA 237
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 238
14.2.2 US 243
14.2.2.1 Robust hospital infrastructure and drug research & development to stimulate growth 243
14.2.3 CANADA 246
14.2.3.1 Growing preference of pharmaceutical companies to conduct trials to favor growth 246
14.3 EUROPE 250
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 250
14.3.2 GERMANY 255
14.3.2.1 Growing focus on reducing approval timelines and high spending by global pharmaceutical players to propel market 255
14.3.3 UK 259
14.3.3.1 Expanding tax credits to encourage growth 259
14.3.4 FRANCE 262
14.3.4.1 Evolving regulatory landscape to stimulate growth 262
14.3.5 ITALY 266
14.3.5.1 Increasing number of drug approvals to accelerate growth 266
14.3.6 SPAIN 269
14.3.6.1 Favorable clinical trial network in public health system to sustain growth 269
14.3.7 SWITZERLAND 272
14.3.7.1 Presence of multinational corporations and small and medium-sized pharmaceutical companies to fuel market 272
14.3.8 NETHERLANDS 276
14.3.8.1 Increasing collaborations among pharmaceutical giants to promote growth 276
14.3.9 REST OF EUROPE 279
14.4 ASIA PACIFIC 283
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 283
14.4.2 CHINA 288
14.4.2.1 High proportion of domestic industry-sponsored trials to speed up growth 288
14.4.3 JAPAN 292
14.4.3.1 Increasing focus on lowering regulatory timelines to facilitate growth 292
14.4.4 INDIA 295
14.4.4.1 Rise in early-phase clinical trials to spur growth 295
14.4.5 AUSTRALIA 299
14.4.5.1 Increasing research funding to favor growth 299
14.4.6 SOUTH KOREA 302
14.4.6.1 Growing focus on new drug development research to drive market 302
14.4.7 SINGAPORE 306
14.4.7.1 Advanced research facilities to intensify growth 306
14.4.8 REST OF ASIA PACIFIC 309
14.5 LATIN AMERICA 313
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 313
14.5.2 BRAZIL 317
14.5.2.1 Regulatory improvements to support growth 317
14.5.3 MEXICO 321
14.5.3.1 Expanding landscape of clinical trials to boost market 321
14.5.4 REST OF LATIN AMERICA 324
14.6 MIDDLE EAST 327
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 327
14.6.2 GCC COUNTRIES 332
14.6.2.1 Saudi Arabia 335
14.6.2.1.1 Booming investments in research infrastructure and life sciences development to aid growth 335
14.6.2.2 UAE 339
14.6.2.2.1 Increasing public-private partnerships and genomic research initiatives to augment growth 339
14.6.2.3 Rest of GCC Countries 342
14.6.3 REST OF MIDDLE EAST 345
14.7 AFRICA 348
14.7.1 GROWING DEMAND FOR OUTSOURCING SERVICES TO DRIVE MARKET GROWTH 348
14.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 349
15 COMPETITIVE LANDSCAPE 353
15.1 INTRODUCTION 353
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 353
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET 353
15.3 REVENUE ANALYSIS, 2023–2025 355
15.4 MARKET SHARE ANALYSIS, 2025 356
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 358
15.5.1 STARS 358
15.5.2 EMERGING LEADERS 358
15.5.3 PERVASIVE PLAYERS 358
15.5.4 PARTICIPANTS 358
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 360
15.5.5.1 Company footprint 360
15.5.5.2 Region footprint 360
15.5.5.3 Service footprint 361
15.5.5.4 Type footprint 362
15.5.5.5 End-user footprint 363
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 364
15.6.1 PROGRESSIVE COMPANIES 364
15.6.2 RESPONSIVE COMPANIES 364
15.6.3 DYNAMIC COMPANIES 364
15.6.4 STARTING BLOCKS 364
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 366
15.6.5.1 Detailed list of key startups/SMEs 366
15.6.5.2 Competitive benchmarking of key startups/SMEs 367
15.7 COMPANY VALUATION & FINANCIAL METRICS 368
15.7.1 COMPANY VALUATION 368
15.7.2 FINANCIAL METRICS 368
15.8 BRAND/SERVICE COMPARISON 369
15.9 COMPETITIVE SCENARIO 370
15.9.1 DEALS 370
15.9.2 EXPANSIONS 370
16 COMPANY PROFILES 372
16.1 KEY PLAYERS 372
16.1.1 THERMO FISHER SCIENTIFIC INC. 372
16.1.1.1 Business overview 372
16.1.1.2 Services offered 373
16.1.1.3 Recent developments 374
16.1.1.3.1 Service launches 374
16.1.1.3.2 Expansions 375
16.1.1.4 MnM view 375
16.1.1.4.1 Right to win 375
16.1.1.4.2 Strategic choices 375
16.1.1.4.3 Weaknesses & competitive threats 376
16.1.2 NOVO HOLDINGS A/S (CATALENT, INC.) 377
16.1.2.1 Business overview 377
16.1.2.2 Services offered 378
16.1.2.3 Recent developments 379
16.1.2.3.1 Deals 379
16.1.2.3.2 Expansions 380
16.1.2.4 MnM view 380
16.1.2.4.1 Right to win 380
16.1.2.4.2 Strategic choices 380
16.1.2.4.3 Weaknesses & competitive threats 380

16.1.3 UNITED PARCEL SERVICE OF AMERICA, INC. 381
16.1.3.1 Business overview 381
16.1.3.2 Services offered 382
16.1.3.3 Recent developments 383
16.1.3.3.1 Deals 383
16.1.3.3.2 Expansions 383
16.1.3.4 MnM view 384
16.1.3.4.1 Right to win 384
16.1.3.4.2 Strategic choices 384
16.1.3.4.3 Weaknesses & competitive threats 384
16.1.4 EUROFINS SCIENTIFIC 385
16.1.4.1 Business overview 385
16.1.4.2 Services offered 386
16.1.4.3 Recent developments 387
16.1.4.3.1 Expansions 387
16.1.4.3.2 Other developments 388
16.1.4.4 MnM view 388
16.1.4.4.1 Right to win 388
16.1.4.4.2 Strategic choices 388
16.1.4.4.3 Weaknesses & competitive threats 388
16.1.5 PIRAMAL PHARMA LIMITED 389
16.1.5.1 Business overview 389
16.1.5.2 Services offered 390
16.1.5.3 Recent developments 391
16.1.5.3.1 Deals 391
16.1.5.3.2 Expansions 391
16.1.5.4 MnM view 392
16.1.5.4.1 Right to win 392
16.1.5.4.2 Strategic choices 392
16.1.5.4.3 Weaknesses & competitive threats 392
16.1.6 IQVIA 393
16.1.6.1 Business overview 393
16.1.6.2 Services offered 395
16.1.7 ICON PLC 396
16.1.7.1 Business overview 396
16.1.7.2 Services offered 397
16.1.7.3 Recent developments 398
16.1.7.3.1 Service launches 398
16.1.7.3.2 Deals 398

16.1.8 LONZA 399
16.1.8.1 Business overview 399
16.1.8.2 Services offered 400
16.1.8.3 Recent developments 400
16.1.8.3.1 Deals 400
16.1.8.3.2 Expansions 401
16.1.9 UNIPHAR GROUP PLC 402
16.1.9.1 Business overview 402
16.1.9.2 Services offered 403
16.1.9.3 Recent developments 404
16.1.9.3.1 Deals 404
16.1.9.3.2 Expansions 404
16.1.10 ALMAC GROUP 405
16.1.10.1 Business overview 405
16.1.10.2 Services offered 405
16.1.10.3 Recent developments 406
16.1.10.3.1 Service launches 406
16.1.10.3.2 Expansions 406
16.1.11 SHARP SERVICES, LLC 407
16.1.11.1 Business overview 407
16.1.11.2 Services offered 407
16.1.11.3 Recent developments 408
16.1.11.3.1 Deals 408
16.1.11.3.2 Expansions 409
16.1.12 PCI PHARMA SERVICES 410
16.1.12.1 Business overview 410
16.1.12.2 Services offered 410
16.1.12.3 Recent developments 411
16.1.12.3.1 Deals 411
16.1.12.3.2 Expansions 411
16.1.13 PAREXEL INTERNATIONAL (MA) CORPORATION 413
16.1.13.1 Business overview 413
16.1.13.2 Services offered 413
16.1.14 BIOCAIR 414
16.1.14.1 Business overview 414
16.1.14.2 Services offered 414
16.2 OTHER PLAYERS 415
16.2.1 CENCORA, INC. 415
16.2.2 CLINIGEN LIMITED 416
16.2.3 KLIFO 417
16.2.4 IPS PHARMA 418
16.2.5 COREX LOGISTICS LIMITED 419
16.2.6 OCT GROUP LLC 420
16.2.7 MYONEX 421
16.2.8 INCEPTUA GROUP 422
16.2.9 ANCILLARE, LP 423
16.2.10 ADALLEN PHARMA 424
16.2.11 CLINICAL SERVICES INTERNATIONAL (CSI) 425
16.2.12 NUVISAN GMBH 426
16.2.13 AENOVA HOLDING GMBH 427
17 RESEARCH METHODOLOGY 428
17.1 RESEARCH DATA 428
17.1.1 SECONDARY DATA 429
17.1.2 PRIMARY RESEARCH 430
17.2 MARKET SIZE ESTIMATION 431
17.2.1 GLOBAL MARKET ESTIMATION 431
17.2.1.1 Insights from primary experts 433
17.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 434
17.3 MARKET GROWTH RATE PROJECTIONS 435
17.4 DATA TRIANGULATION 438
17.5 RESEARCH ASSUMPTIONS 439
17.6 RESEARCH LIMITATIONS 440
17.7 RISK ANALYSIS 440
18 APPENDIX 441
18.1 DISCUSSION GUIDE 441
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 445
18.3 CUSTOMIZATION OPTIONS 447
18.4 RELATED REPORTS 447
18.5 AUTHOR DETAILS 448

LIST OF TABLES

TABLE 1 CLINICAL TRIAL SUPPLIES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 57
TABLE 2 CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS 63
TABLE 3 CLINICAL TRIAL SUPPLIES MARKET: PRODUCT MANUFACTURERS 69
TABLE 4 CLINICAL TRIAL SUPPLIES MARKET: SERVICE PROVIDERS 70
TABLE 5 CLINICAL TRIAL SUPPLIES MARKET: END USERS 70
TABLE 6 CLINICAL TRIAL SUPPLIES MARKET: REGULATORY BODIES 71
TABLE 7 CLINICAL TRIAL SUPPLIES MARKET: KEY CONFERENCES AND EVENTS,
2026–2027 75
TABLE 8 CASE STUDIES OF AI-ENABLED CLINICAL-TRIAL OPERATIONS AND SUPPLY IMPACT 83
TABLE 9 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN CLINICAL TRIAL SUPPLIES MARKET 84
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES, BY TYPE 92
TABLE 16 KEY BUYING CRITERIA, BY END USER 93
TABLE 17 CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2031 (USD MILLION) 98
TABLE 18 CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES,
BY REGION, 2023–2031 (USD MILLION) 99
TABLE 19 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 99
TABLE 20 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 100
TABLE 21 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 100
TABLE 22 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 101
TABLE 23 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY REGION, 2023–2031 (USD MILLION) 101
TABLE 24 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR LOGISTICS & DISTRIBUTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 101
TABLE 25 CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES,
BY REGION, 2023–2031 (USD MILLION) 102
TABLE 26 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 103
TABLE 27 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 103
TABLE 28 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 104
TABLE 29 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 104
TABLE 30 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY REGION, 2023–2031 (USD MILLION) 104
TABLE 31 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR STORAGE & RETENTION SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 105
TABLE 32 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 105
TABLE 33 CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2023–2031 (USD MILLION) 106
TABLE 34 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 106
TABLE 35 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 107
TABLE 36 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 107
TABLE 37 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 108
TABLE 38 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY REGION, 2023–2031 (USD MILLION) 108
TABLE 39 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 108
TABLE 40 PRIMARY PACKAGING SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 109
TABLE 41 NORTH AMERICA: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 109
TABLE 42 EUROPE: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 110
TABLE 43 ASIA PACIFIC: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 110
TABLE 44 LATIN AMERICA: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 111
TABLE 45 MIDDLE EAST: PRIMARY PACKAGING SERVICES MARKET, BY REGION,
2023–2031 (USD MILLION) 111
TABLE 46 GCC COUNTRIES: PRIMARY PACKAGING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 111
TABLE 47 SECONDARY PACKAGING SERVICES MARKET, BY REGION,
2023–2031 (USD MILLION) 112
TABLE 48 NORTH AMERICA: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 112
TABLE 49 EUROPE: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 113
TABLE 50 ASIA PACIFIC: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 113
TABLE 51 LATIN AMERICA: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114
TABLE 52 MIDDLE EAST: SECONDARY PACKAGING SERVICES MARKET, BY REGION,
2023–2031 (USD MILLION) 114
TABLE 53 GCC COUNTRIES: SECONDARY PACKAGING SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114
TABLE 54 LABELING & BLINDING SERVICES MARKET, BY REGION,
2023–2031 (USD MILLION) 115
TABLE 55 NORTH AMERICA: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 115
TABLE 56 EUROPE: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 116
TABLE 57 ASIA PACIFIC: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 116
TABLE 58 LATIN AMERICA: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 117
TABLE 59 MIDDLE EAST: LABELING & BLINDING SERVICES MARKET, BY REGION,
2023–2031 (USD MILLION) 117
TABLE 60 GCC COUNTRIES: LABELING & BLINDING SERVICES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 117
TABLE 61 CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2031 (USD MILLION) 118
TABLE 62 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 119
TABLE 63 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 119
TABLE 64 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 120
TABLE 65 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 120
TABLE 66 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY REGION, 2023–2031 (USD MILLION) 120
TABLE 67 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MANUFACTURING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 121
TABLE 68 CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES,
BY REGION, 2023–2031 (USD MILLION) 122
TABLE 69 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 122
TABLE 70 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 123
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 123
TABLE 72 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 124
TABLE 73 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY REGION, 2023–2031 (USD MILLION) 124
TABLE 74 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR COMPARATOR SOURCING SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 124
TABLE 75 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY REGION,
2023–2031 (USD MILLION) 125
TABLE 76 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 126
TABLE 77 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2031 (USD MILLION) 126
TABLE 78 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 127
TABLE 79 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 127
TABLE 80 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,
BY REGION, 2023–2031 (USD MILLION) 127
TABLE 81 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER SERVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 128
TABLE 82 CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 130
TABLE 83 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY REGION,
2023–2031 (USD MILLION) 131
TABLE 84 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 131
TABLE 85 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS, BY COUNTRY, 2023–2031 (USD MILLION) 132
TABLE 86 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 132
TABLE 87 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 133
TABLE 88 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,
BY REGION, 2023–2031 (USD MILLION) 133
TABLE 89 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE III TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 133
TABLE 90 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY REGION,
2023–2031 (USD MILLION) 134
TABLE 91 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 135
TABLE 92 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS, BY COUNTRY, 2023–2031 (USD MILLION) 135
TABLE 93 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 136
TABLE 94 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 136
TABLE 95 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,
BY REGION, 2023–2031 (USD MILLION) 136
TABLE 96 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE II TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 137
TABLE 97 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY REGION,
2023–2031 (USD MILLION) 138
TABLE 98 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 138
TABLE 99 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS, BY COUNTRY, 2023–2031 (USD MILLION) 139
TABLE 100 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 139
TABLE 101 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 140
TABLE 102 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,
BY REGION, 2023–2031 (USD MILLION) 140
TABLE 103 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE I TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 140
TABLE 104 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY REGION,
2023–2031 (USD MILLION) 141
TABLE 105 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 142
TABLE 106 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS, BY COUNTRY, 2023–2031 (USD MILLION) 142
TABLE 107 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 143
TABLE 108 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 143
TABLE 109 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,
BY REGION, 2023–2031 (USD MILLION) 143
TABLE 110 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE IV TRIALS,
BY COUNTRY, 2023–2031 (USD MILLION) 144
TABLE 111 CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY REGION, 2023–2031 (USD MILLION) 145
TABLE 112 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2031 (USD MILLION) 145
TABLE 113 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES,
BY COUNTRY, 2023–2031 (USD MILLION) 146
TABLE 114 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES,
BY COUNTRY, 2023–2031 (USD MILLION) 146
TABLE 115 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2031 (USD MILLION) 147
TABLE 116 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES,
BY REGION, 2023–2031 (USD MILLION) 147
TABLE 117 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHASE BA/BE STUDIES, BY COUNTRY, 2023–2031 (USD MILLION) 147
TABLE 118 CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 149
TABLE 119 CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES, BY REGION,
2023–2031 (USD MILLION) 150
TABLE 120 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2031 (USD MILLION) 150
TABLE 121 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2031 (USD MILLION) 151
TABLE 122 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2031 (USD MILLION) 151
TABLE 123 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2031 (USD MILLION) 152
TABLE 124 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,
BY REGION, 2023–2031 (USD MILLION) 152
TABLE 125 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2031 (USD MILLION) 152
TABLE 126 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 153
TABLE 127 CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY REGION,
2023–2031 (USD MILLION) 154
TABLE 128 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,
BY COUNTRY, 2023–2031 (USD MILLION) 154
TABLE 129 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY,
2023–2031 (USD MILLION) 155
TABLE 130 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2031 (USD MILLION) 155
TABLE 131 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY COUNTRY, 2023–2031 (USD MILLION) 156
TABLE 132 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY REGION, 2023–2031 (USD MILLION) 156
TABLE 133 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,
BY COUNTRY, 2023–2031 (USD MILLION) 156
TABLE 134 CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2031 (USD MILLION) 157
TABLE 135 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD MILLION) 158
TABLE 136 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2023–2031 (USD MILLION) 158
TABLE 137 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD MILLION) 159
TABLE 138 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD MILLION) 159
TABLE 139 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2031 (USD MILLION) 159
TABLE 140 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2031 (USD MILLION) 160
TABLE 141 CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY REGION,
2023–2031 (USD MILLION) 161
TABLE 142 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES,
BY COUNTRY, 2023–2031 (USD MILLION) 161
TABLE 143 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY,
2023–2031 (USD MILLION) 162
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2031 (USD MILLION) 162
TABLE 145 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2031 (USD MILLION) 163
TABLE 146 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY REGION, 2023–2031 (USD MILLION) 163
TABLE 147 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR VACCINES, BY COUNTRY, 2023–2031 (USD MILLION) 163
TABLE 148 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY REGION,
2023–2031 (USD MILLION) 164
TABLE 149 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,
BY COUNTRY, 2023–2031 (USD MILLION) 165
TABLE 150 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2031 (USD MILLION) 165
TABLE 151 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,
BY COUNTRY, 2023–2031 (USD MILLION) 166
TABLE 152 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,
BY COUNTRY, 2023–2031 (USD MILLION) 166
TABLE 153 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,
BY REGION, 2023–2031 (USD MILLION) 166
TABLE 154 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER BIOLOGICS,
BY COUNTRY, 2023–2031 (USD MILLION) 167
TABLE 155 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY REGION,
2023–2031 (USD MILLION) 168
TABLE 156 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 168
TABLE 157 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2031 (USD MILLION) 169
TABLE 158 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 169
TABLE 159 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 170
TABLE 160 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,
BY REGION, 2023–2031 (USD MILLION) 170
TABLE 161 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICES,
BY COUNTRY, 2023–2031 (USD MILLION) 170
TABLE 162 CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 172
TABLE 163 US: NUMBER OF NEW CANCER CASES, BY TYPE, 2022 VS. 2040 173
TABLE 164 CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION,
2023–2031 (USD MILLION) 174
TABLE 165 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 174
TABLE 166 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 175
TABLE 167 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 175
TABLE 168 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 176
TABLE 169 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY, BY REGION, 2023–2031 (USD MILLION) 176
TABLE 170 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 176
TABLE 171 CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION,
2023–2031 (USD MILLION) 178
TABLE 172 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 178
TABLE 173 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 179
TABLE 174 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 179
TABLE 175 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 180
TABLE 176 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY, BY REGION, 2023–2031 (USD MILLION) 180
TABLE 177 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR NEUROLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 180
TABLE 178 CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2031 (USD MILLION) 181
TABLE 179 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 182
TABLE 180 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS,
BY COUNTRY, 2023–2031 (USD MILLION) 182
TABLE 181 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 183
TABLE 182 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 183
TABLE 183 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2023–2031 (USD MILLION) 183
TABLE 184 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 184
TABLE 185 CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2031 (USD MILLION) 185
TABLE 186 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 185
TABLE 187 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 186
TABLE 188 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 186
TABLE 189 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 187
TABLE 190 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2031 (USD MILLION) 187
TABLE 191 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 187
TABLE 192 CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2031 (USD MILLION) 188
TABLE 193 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 189
TABLE 194 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 189
TABLE 195 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 190
TABLE 196 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 190
TABLE 197 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2031 (USD MILLION) 190
TABLE 198 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 191
TABLE 199 CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY REGION,
2023–2031 (USD MILLION) 192
TABLE 200 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 192
TABLE 201 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 193
TABLE 202 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 193
TABLE 203 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 194
TABLE 204 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,
BY REGION, 2023–2031 (USD MILLION) 194
TABLE 205 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 194
TABLE 206 CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY REGION, 2023–2031 (USD MILLION) 195
TABLE 207 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 196
TABLE 208 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 196
TABLE 209 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 197
TABLE 210 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 197
TABLE 211 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY REGION, 2023–2031 (USD MILLION) 198
TABLE 212 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR GASTROINTESTINAL SYSTEM DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 198
TABLE 213 CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS,
BY REGION, 2023–2031 (USD MILLION) 199
TABLE 214 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 199
TABLE 215 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 200
TABLE 216 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 200
TABLE 217 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 201
TABLE 218 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2031 (USD MILLION) 201
TABLE 219 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2031 (USD MILLION) 201
TABLE 220 CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION) 203
TABLE 221 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 203
TABLE 222 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 204
TABLE 223 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2031 (USD MILLION) 204
TABLE 224 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 205
TABLE 225 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2023–2031 (USD MILLION) 205
TABLE 226 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 205
TABLE 227 CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY REGION,
2023–2031 (USD MILLION) 206
TABLE 228 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY,
BY COUNTRY, 2023–2031 (USD MILLION) 207
TABLE 229 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2031 (USD MILLION) 207
TABLE 230 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY COUNTRY, 2023–2031 (USD MILLION) 208
TABLE 231 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY,
BY COUNTRY, 2023–2031 (USD MILLION) 208
TABLE 232 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY, BY REGION, 2023–2031 (USD MILLION) 208
TABLE 233 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PSYCHIATRY,
BY COUNTRY, 2023–2031 (USD MILLION) 209
TABLE 234 CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY REGION,
2023–2031 (USD MILLION) 210
TABLE 235 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 210
TABLE 236 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 211
TABLE 237 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 211
TABLE 238 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 212
TABLE 239 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,
BY REGION, 2023–2031 (USD MILLION) 212
TABLE 240 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 212
TABLE 241 CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY REGION,
2023–2031 (USD MILLION) 213
TABLE 242 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 214
TABLE 243 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 214
TABLE 244 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 215
TABLE 245 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 215
TABLE 246 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY, BY REGION, 2023–2031 (USD MILLION) 215
TABLE 247 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2023–2031 (USD MILLION) 216
TABLE 248 CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,
BY REGION, 2023–2031 (USD MILLION) 217
TABLE 249 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2031 (USD MILLION) 217
TABLE 250 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2031 (USD MILLION) 218
TABLE 251 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2031 (USD MILLION) 218
TABLE 252 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2031 (USD MILLION) 219
TABLE 253 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2023–2031 (USD MILLION) 219
TABLE 254 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2031 (USD MILLION) 219
TABLE 255 CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2031 (USD MILLION) 220
TABLE 256 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 221
TABLE 257 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2023–2031 (USD MILLION) 221
TABLE 258 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 222
TABLE 259 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 222
TABLE 260 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2031 (USD MILLION) 222
TABLE 261 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2031 (USD MILLION) 223
TABLE 262 CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2031 (USD MILLION) 225
TABLE 263 CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 226
TABLE 264 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 226
TABLE 265 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 227
TABLE 266 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 227
TABLE 267 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 228
TABLE 268 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2031 (USD MILLION) 228
TABLE 269 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 228
TABLE 270 CLINICAL TRIAL SUPPLIES MARKET FOR CROS, BY REGION,
2023–2031 (USD MILLION) 229
TABLE 271 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CROS, BY COUNTRY, 2023–2031 (USD MILLION) 230
TABLE 272 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR CROS, BY COUNTRY,
2023–2031 (USD MILLION) 230
TABLE 273 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR CROS, BY COUNTRY,
2023–2031 (USD MILLION) 231
TABLE 274 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR CROS, BY COUNTRY, 2023–2031 (USD MILLION) 231
TABLE 275 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR CROS, BY REGION,
2023–2031 (USD MILLION) 231
TABLE 276 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR CROS, BY COUNTRY, 2023–2031 (USD MILLION) 232
TABLE 277 CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2023–2031 (USD MILLION) 233
TABLE 278 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 233
TABLE 279 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 234
TABLE 280 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 234
TABLE 281 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 235
TABLE 282 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2023–2031 (USD MILLION) 235
TABLE 283 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2031 (USD MILLION) 235
TABLE 284 CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2023–2031 (USD MILLION) 237
TABLE 285 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 238
TABLE 286 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 239
TABLE 287 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 240
TABLE 288 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 240
TABLE 289 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 241
TABLE 290 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 241
TABLE 291 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 241
TABLE 292 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 242
TABLE 293 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 242
TABLE 294 US: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2031 (USD MILLION) 243
TABLE 295 US: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 244
TABLE 296 US: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 244
TABLE 297 US: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 244
TABLE 298 US: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 245
TABLE 299 US: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 245
TABLE 300 US: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2031 (USD MILLION) 246
TABLE 301 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 247
TABLE 302 CANADA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 247
TABLE 303 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 248
TABLE 304 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 248
TABLE 305 CANADA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 248
TABLE 306 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 249
TABLE 307 CANADA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 249
TABLE 308 EUROPE: KEY MACROECONOMIC INDICATORS 251
TABLE 309 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 251
TABLE 310 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 252
TABLE 311 EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 252
TABLE 312 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 253
TABLE 313 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 253
TABLE 314 EUROPE: CLINICAL TRIAL SUPPLIES MARKE FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 253
TABLE 315 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 254
TABLE 316 EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 254
TABLE 317 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 256
TABLE 318 GERMANY: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 256
TABLE 319 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 257
TABLE 320 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 257
TABLE 321 GERMANY: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 257
TABLE 322 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 258
TABLE 323 GERMANY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 258
TABLE 324 UK: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2031 (USD MILLION) 259
TABLE 325 UK: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 260
TABLE 326 UK: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 260
TABLE 327 UK: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 260
TABLE 328 UK: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 261
TABLE 329 UK: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 261
TABLE 330 UK: CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2023–2031 (USD MILLION) 262
TABLE 331 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 263
TABLE 332 FRANCE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 263
TABLE 333 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 264
TABLE 334 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 264
TABLE 335 FRANCE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 264
TABLE 336 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 265
TABLE 337 FRANCE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 265
TABLE 338 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 266
TABLE 339 ITALY: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 267
TABLE 340 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 267
TABLE 341 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 267
TABLE 342 ITALY: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 268
TABLE 343 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 268
TABLE 344 ITALY: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 269
TABLE 345 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 269
TABLE 346 SPAIN: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 270
TABLE 347 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 270
TABLE 348 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 270
TABLE 349 SPAIN: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 271
TABLE 350 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 271
TABLE 351 SPAIN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 272
TABLE 352 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 273
TABLE 353 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 273
TABLE 354 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 274
TABLE 355 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 274
TABLE 356 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 274
TABLE 357 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 275
TABLE 358 SWITZERLAND: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 275
TABLE 359 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 276
TABLE 360 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 277
TABLE 361 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 277
TABLE 362 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 277
TABLE 363 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 278
TABLE 364 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 278
TABLE 365 NETHERLANDS: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 279
TABLE 366 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 280
TABLE 367 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 280
TABLE 368 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 281
TABLE 369 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 281
TABLE 370 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 281
TABLE 371 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 282
TABLE 372 REST OF EUROPE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 282
TABLE 373 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 284
TABLE 374 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 285
TABLE 375 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 285
TABLE 376 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 286
TABLE 377 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 286
TABLE 378 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 286
TABLE 379 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 287
TABLE 380 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 287
TABLE 381 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 288
TABLE 382 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 289
TABLE 383 CHINA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 289
TABLE 384 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 290
TABLE 385 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 290
TABLE 386 CHINA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 290
TABLE 387 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 291
TABLE 388 CHINA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 291
TABLE 389 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 292
TABLE 390 JAPAN: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 293
TABLE 391 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 293
TABLE 392 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 293
TABLE 393 JAPAN: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 294
TABLE 394 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 294
TABLE 395 JAPAN: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 295
TABLE 396 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 296
TABLE 397 INDIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 296
TABLE 398 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 297
TABLE 399 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 297
TABLE 400 INDIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 297
TABLE 401 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 298
TABLE 402 INDIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 298
TABLE 403 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 299
TABLE 404 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 300
TABLE 405 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 300
TABLE 406 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 300
TABLE 407 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 301
TABLE 408 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 301
TABLE 409 AUSTRALIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 302
TABLE 410 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 303
TABLE 411 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 303
TABLE 412 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 304
TABLE 413 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 304
TABLE 414 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 304
TABLE 415 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 305
TABLE 416 SOUTH KOREA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 305
TABLE 417 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 306
TABLE 418 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 307
TABLE 419 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 307
TABLE 420 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 307
TABLE 421 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 308
TABLE 422 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 308
TABLE 423 SINGAPORE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 309
TABLE 424 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 310
TABLE 425 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 310
TABLE 426 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 311
TABLE 427 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 311
TABLE 428 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,
BY TYPE, 2023–2031 (USD MILLION) 311
TABLE 429 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 312
TABLE 430 REST OF ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 312
TABLE 431 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 314
TABLE 432 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 314
TABLE 433 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 314
TABLE 434 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 315
TABLE 435 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 315
TABLE 436 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 315
TABLE 437 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 316
TABLE 438 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 316
TABLE 439 LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 317
TABLE 440 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 318
TABLE 441 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 318
TABLE 442 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 319
TABLE 443 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 319
TABLE 444 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 319
TABLE 445 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 320
TABLE 446 BRAZIL: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 320
TABLE 447 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 321
TABLE 448 MEXICO: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 322
TABLE 449 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 322
TABLE 450 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 322
TABLE 451 MEXICO: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 323
TABLE 452 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 323
TABLE 453 MEXICO: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 324
TABLE 454 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 324
TABLE 455 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 325
TABLE 456 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 325
TABLE 457 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 325
TABLE 458 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,
BY TYPE, 2023–2031 (USD MILLION) 326
TABLE 459 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET,
BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 326
TABLE 460 REST OF LATIN AMERICA: CLINICAL TRIAL SUPPLIES MARKET,
BY END USER, 2023–2031 (USD MILLION) 327
TABLE 461 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 328
TABLE 462 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY REGION,
2023–2031 (USD MILLION) 328
TABLE 463 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 329
TABLE 464 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 329
TABLE 465 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 330
TABLE 466 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 330
TABLE 467 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 330
TABLE 468 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 331
TABLE 469 MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 331
TABLE 470 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY,
2023–2031 (USD MILLION) 332
TABLE 471 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 332
TABLE 472 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 333
TABLE 473 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 333
TABLE 474 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 333
TABLE 475 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 334
TABLE 476 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 334
TABLE 477 GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 335
TABLE 478 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 336
TABLE 479 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 336
TABLE 480 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 337
TABLE 481 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 337
TABLE 482 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE, 2023–2031 (USD MILLION) 337
TABLE 483 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 338
TABLE 484 SAUDI ARABIA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 338
TABLE 485 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE, 2023–2031 (USD MILLION) 339
TABLE 486 UAE: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 340
TABLE 487 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE, 2023–2031 (USD MILLION) 340
TABLE 488 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 340
TABLE 489 UAE: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 341
TABLE 490 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 341
TABLE 491 UAE: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 342
TABLE 492 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 342
TABLE 493 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 343
TABLE 494 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 343
TABLE 495 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 343
TABLE 496 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,
BY TYPE, 2023–2031 (USD MILLION) 344
TABLE 497 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET,
BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 344
TABLE 498 REST OF GCC COUNTRIES: CLINICAL TRIAL SUPPLIES MARKET,
BY END USER, 2023–2031 (USD MILLION) 345
TABLE 499 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 345
TABLE 500 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 346
TABLE 501 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 346
TABLE 502 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE,
2023–2031 (USD MILLION) 346
TABLE 503 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS,
BY TYPE, 2023–2031 (USD MILLION) 347
TABLE 504 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET,
BY THERAPEUTIC AREA, 2023–2031 (USD MILLION) 347
TABLE 505 REST OF MIDDLE EAST: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 348
TABLE 506 AFRICA: KEY MACROECONOMIC INDICATORS 349
TABLE 507 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY SERVICE,
2023–2031 (USD MILLION) 349
TABLE 508 AFRICA: CLINICAL TRIAL SUPPLIES MARKET FOR PACKAGING, LABELING, AND BLINDING SERVICES, BY TYPE, 2023–2031 (USD MILLION) 350
TABLE 509 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY PHASE,
2023–2031 (USD MILLION) 350
TABLE 510 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY TYPE, 2023–2031 (USD MILLION) 350
TABLE 511 AFRICA: CLINICAL TRIAL SUPPLIES MARKET FOR BIOLOGICS, BY TYPE,
2023–2031 (USD MILLION) 351
TABLE 512 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC AREA,
2023–2031 (USD MILLION) 351
TABLE 513 AFRICA: CLINICAL TRIAL SUPPLIES MARKET, BY END USER,
2023–2031 (USD MILLION) 352
TABLE 514 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN THE CLINICAL TRIAL SUPPLIES MARKET 353
TABLE 515 CLINICAL TRIAL SUPPLIES MARKET: DEGREE OF COMPETITION 356
TABLE 516 CLINICAL TRIALS SUPPLIES MARKET: REGION FOOTPRINT 360
TABLE 517 CLINICAL TRIAL SUPPLIES MARKET: SERVICE FOOTPRINT 361
TABLE 518 CLINICAL TRIAL SUPPLIES MARKET: TYPE FOOTPRINT 362
TABLE 519 CLINICAL TRIAL SUPPLIES MARKET: END-USER FOOTPRINT 363
TABLE 520 CLINICAL TRIAL SUPPLIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 366
TABLE 521 CLINICAL TRIAL SUPPLIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 367
TABLE 522 CLINICAL TRIAL SUPPLIES MARKET: DEALS, JANUARY 2023–AUGUST 2026 370
TABLE 523 CLINICAL TRIAL SUPPLIES MARKET: EXPANSIONS, JANUARY 2023–AUGUST 2026 370
TABLE 524 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 372
TABLE 525 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 373
TABLE 526 THERMO FISHER SCIENTIFIC INC.: SERVICE LAUNCHES,
JANUARY 2023–AUGUST 2026 374
TABLE 527 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–AUGUST 2026 375
TABLE 528 NOVO HOLDINGS A/S: COMPANY OVERVIEW 377
TABLE 529 NOVO HOLDINGS A/S (CATALENT, INC.): SERVICES OFFERED 378
TABLE 530 NOVO HOLDINGS A/S (CATALENT, INC.): DEALS, JANUARY 2023–AUGUST 2026 379
TABLE 531 NOVO HOLDINGS A/S (CATALENT, INC.): EXPANSIONS,
JANUARY 2023–AUGUST 2026 380
TABLE 532 UNITED PARCEL SERVICE OF AMERICA, INC.: COMPANY OVERVIEW 381
TABLE 533 UNITED PARCEL SERVICE OF AMERICA, INC.: SERVICES OFFERED 382
TABLE 534 UNITED PARCEL SERVICE OF AMERICA, INC. (US): DEALS,
JANUARY 2023–AUGUST 2026 383
TABLE 535 UNITED PARCEL SERVICE OF AMERICA, INC. (US): EXPANSIONS,
JANUARY 2023–AUGUST 2026 383
TABLE 536 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 385
TABLE 537 EUROFINS SCIENTIFIC: SERVICES OFFERED 386
TABLE 538 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–AUGUST 2026 387
TABLE 539 EUROFINS SCIENTIFIC: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 388
TABLE 540 PIRAMAL PHARMA LIMITED: COMPANY OVERVIEW 389
TABLE 541 PIRAMAL PHARMA LIMITED: SERVICES OFFERED 390
TABLE 542 PIRAMAL PHARMA LIMITED: DEALS, JANUARY 2023–AUGUST 2026 391
TABLE 543 PIRAMAL PHARMA LIMITED: EXPANSIONS, JANUARY 2023–AUGUST 2026 391
TABLE 544 IQVIA: COMPANY OVERVIEW 393
TABLE 545 IQVIA: SERVICES OFFERED 395
TABLE 546 ICON PLC: COMPANY OVERVIEW 396
TABLE 547 ICON PLC: SERVICES OFFERED 397
TABLE 548 ICON PLC: SERVICE LAUNCHES, JANUARY 2023–AUGUST 2026 398
TABLE 549 ICON PLC: DEALS, JANUARY 2023–AUGUST 2026 398
TABLE 550 LONZA: COMPANY OVERVIEW 399
TABLE 551 LONZA: SERVICES OFFERED 400
TABLE 552 LONZA: DEALS, JANUARY 2023–AUGUST 2026 400
TABLE 553 LONZA: EXPANSIONS, JANUARY 2023–AUGUST 2026 401
TABLE 554 UNIPHAR GROUP PLC: COMPANY OVERVIEW 402
TABLE 555 UNIPHAR GROUP PLC: SERVICES OFFERED 403
TABLE 556 UNIPHAR GROUP PLC: DEALS, JANUARY 2023–AUGUST 2026 404
TABLE 557 UNIPHAR GROUP PLC: EXPANSIONS, JANUARY 2023–AUGUST 2026 404
TABLE 558 ALMAC GROUP: COMPANY OVERVIEW 405
TABLE 559 ALMAC GROUP: SERVICES OFFERED 405
TABLE 560 ALMAC GROUP: SERVICE LAUNCHES, JANUARY 2023–AUGUST 2026 406
TABLE 561 ALMAC GROUP: EXPANSIONS, JANUARY 2023–AUGUST 2026 406
TABLE 562 SHARP SERVICES, LLC: COMPANY OVERVIEW 407
TABLE 563 SHARP SERVICES, LLC: SERVICES OFFERED 407
TABLE 564 SHARP SERVICES, LLC: DEALS, JANUARY 2023–AUGUST 2026 408
TABLE 565 SHARP SERVICES, LLC: EXPANSIONS, JANUARY 2023–AUGUST 2026 409
TABLE 566 PCI PHARMA SERVICES: COMPANY OVERVIEW 410
TABLE 567 PCI PHARMA SERVICES: SERVICES OFFERED 410
TABLE 568 PCI PHARMA SERVICES: DEALS, JANUARY 2023–AUGUST 2026 411
TABLE 569 PCI PHARMA SERVICES: EXPANSIONS, JANUARY 2023–AUGUST 2026 411
TABLE 570 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW 413
TABLE 571 PAREXEL INTERNATIONAL (MA) CORPORATION: SERVICES OFFERED 413
TABLE 572 BIOCAIR: COMPANY OVERVIEW 414
TABLE 573 BIOCAIR: SERVICES OFFERED 414
TABLE 574 CENCORA, INC.: COMPANY OVERVIEW 415
TABLE 575 CLINIGEN LIMITED: COMPANY OVERVIEW 416
TABLE 576 KLIFO: COMPANY OVERVIEW 417
TABLE 577 IPS PHARMA: COMPANY OVERVIEW 418
TABLE 578 COREX LOGISTICS LIMITED: COMPANY OVERVIEW 419
TABLE 579 OCT GROUP LLC: COMPANY OVERVIEW 420
TABLE 580 MYONEX: COMPANY OVERVIEW 421
TABLE 581 INCEPTUA GROUP: COMPANY OVERVIEW 422
TABLE 582 ANCILLARE, LP: COMPANY OVERVIEW 423
TABLE 583 ADALLEN PHARMA: COMPANY OVERVIEW 424
TABLE 584 CLINICAL SERVICES INTERNATIONAL (CSI): COMPANY OVERVIEW 425
TABLE 585 NUVISAN GMBH: COMPANY OVERVIEW 426
TABLE 586 AENOVA HOLDING GMBH: COMPANY OVERVIEW 427
TABLE 587 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 436
TABLE 588 CLINICAL TRIAL SUPPLIES MARKET: RISK ASSESSMENT ANALYSIS 440

LIST OF FIGURES

FIGURE 1 MARKET SEGMENTATION & GEOGRAPHIC SPREAD 43
FIGURE 2 MARKET SCENARIO 48
FIGURE 3 GLOBAL CLINICAL TRIAL SUPPLIES MARKET, 2024–2031 48
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET, 2023–2025 49
FIGURE 5 DISRUPTIONS INFLUENCING THE GROWTH OF THE CLINICAL TRIAL SUPPLIES MARKET 50
FIGURE 6 HIGH-GROWTH SEGMENTS IN THE CLINICAL TRIAL SUPPLIES MARKET,
2026–2031 51
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN THE CLINICAL TRIAL SUPPLIES MARKET, IN TERMS OF VALUE, DURING THE FORECAST PERIOD 52
FIGURE 8 GROWTH IN CLINICAL TRIALS AND DRUG DEVELOPMENT TO PROPEL MARKET 53
FIGURE 9 SMALL MOLECULES AND BIOLOGICS ACCOUNT FOR LARGEST MARKET SHARE
IN NORTH AMERICA 54
FIGURE 10 SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 54
FIGURE 11 CHINA PROJECTED TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 55
FIGURE 12 CLINICAL TRIAL SUPPLIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
FIGURE 13 CLINICAL TRIAL SUPPLIES MARKET: PORTER’S FIVE FORCES ANALYSIS 64
FIGURE 14 CLINICAL TRIAL SUPPLIES MARKET: VALUE CHAIN ANALYSIS 67
FIGURE 15 CLINICAL TRIAL SUPPLIES MARKET: ECOSYSTEM ANALYSIS 69
FIGURE 16 CLINICAL TRIAL SUPPLIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
FIGURE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SUPPLIES, BY TYPE 92
FIGURE 18 KEY BUYING CRITERIA, BY END USER 93
FIGURE 19 NORTH AMERICA: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 239
FIGURE 20 ASIA PACIFIC: CLINICAL TRIAL SUPPLIES MARKET SNAPSHOT 284
FIGURE 21 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL SUPPLIES MARKET, 2023–2025 (USD MILLION) 355
FIGURE 22 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 356
FIGURE 23 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 359
FIGURE 24 CLINICAL TRIAL SUPPLIES MARKET: COMPANY FOOTPRINT 360
FIGURE 25 CLINICAL TRIAL SUPPLIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 365
FIGURE 26 EV/EBITDA OF KEY VENDORS 368
FIGURE 27 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 368
FIGURE 28 CLINICAL TRIAL SUPPLIES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS 369
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 373
FIGURE 30 NOVO HOLDINGS A/S: COMPANY SNAPSHOT 378
FIGURE 31 UNITED PARCEL SERVICE OF AMERICA, INC.: COMPANY SNAPSHOT 381
FIGURE 32 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 386
FIGURE 33 PIRAMAL PHARMA LIMITED: COMPANY SNAPSHOT 390
FIGURE 34 IQVIA: COMPANY SNAPSHOT 394
FIGURE 35 ICON PLC: COMPANY SNAPSHOT 396
FIGURE 36 LONZA: COMPANY SNAPSHOT 399
FIGURE 37 UNIPHAR GROUP PLC: COMPANY SNAPSHOT 403
FIGURE 38 CLINICAL TRIAL SUPPLIES MARKET: RESEARCH DESIGN 428
FIGURE 39 CLINICAL TRIAL SUPPLIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 430
FIGURE 40 CLINICAL TRIAL SUPPLIES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2025 431
FIGURE 41 CLINICAL TRIAL SUPPLIES MARKET ESTIMATION: APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 432
FIGURE 42 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2025) 432
FIGURE 43 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 433
FIGURE 44 SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 434
FIGURE 45 CLINICAL TRIAL SUPPLIES MARKET: CAGR PROJECTIONS 435
FIGURE 46 DATA TRIANGULATION METHODOLOGY 438


    お問い合わせ

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    お問合せレポート

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    SEMABIZのプライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    inquiry(at)semabiz.co.jp


    関連記事